17.01.2011 • NewsSafcoSABICQ4 2010

Saudi Safco Q4 Net Tripled On Higher Sale Prices

Saudi Arabian Fertilizers Co (Safco) said on Sunday its net profit nearly tripled in the fourth quarter buoyed by higher prices, beating estimates.

Safco made 1 billion ($266.7 million) riyals in the quarter after 376 million riyals a year ago but revised its net profit for the fourth quarter of 2009 to 335 million riyals, the company said in a statement posted on the bourse website.

The results beat analysts' average forecast of 770.23 million riyals.

"The rise in profits for 2010 and the fourth quarter of 2010 compared to the same periods the year earlier ... is due to improving prices of petrochemical products and increasing sales," the statement said.

Saudi Arabian Basic Industries Corp (SABIC) owns a 42.9% stake in Safco.

Operating profit and gross profit for the fourth-quarter both rose by 156% with operating profit reaching 896 million riyals for the fourth-quarter and gross profit reaching 918 million riyals for the same period, the statement said.

Full year net profit rose by 79% to 3.2 billion riyals. Earnings per share for the year reached 12.9 riyals, it said.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.